
Releases
BioArctic and Eli Lilly Partner on Brain-Targeted Drug Delivery
A 30 million dollar upfront payment marks the start of a new collaboration between Sweden’s BioArctic and Eli Lilly, as the companies join forces to pair a proprietary drug-delivery platform with a secret neurodegeneration compound currently held in the American pharmaceutical giant's research pipeline.























